^
Association details:
| Biomarker: | Chr del(5q) + Chr amplification(21)(q22) RUNX1 |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | azacitidine (DNMT inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient
Published date:
11/29/2018
Excerpt:
A 74-year-old female patient with AML that developed 9 years after receiving 6 cycles of cytotoxic (FOLFOX) chemotherapy as adjuvant treatment of colorectal carcinoma. At diagnosis, the bone marrow (BM) biopsy revealed blast count of 35%, with normal karyotype, 5q loss and AML1 (RUNX1) locus (21q22) amplification by fluorescence in situ hybridization (FISH). Initial treatment with 5 cycles of azacitidine (AZA) failed to induce a response.
DOI:
10.1182/blood-2018-99-118522
Trial ID:
